Abstract
The SSRIs have become the most heavily prescribed antidepressant drugs in North America and Europe. However, they have been dogged by controversy about withdrawal effects/drug dependence, heightened suicidal thinking and behaviour, and their use in children and adolescents who are depressed. This paper brings the reader up to date with developments, including opinion and guidance from the MHRA and NICE.
Get full access to this article
View all access options for this article.
References
1.
http://www.mhra.gov.uk/. Report of the CSM Expert Working Group on the safety of selective serotonin reuptake inhibitor antidepressants. Accessed 6 December 2004 .
2.
Management of depression in primary and secondary care. Clinical Guideline 23. www.nice.org.uk/guidance/CG23 Accessed 6 December 2004 .
3.
Van Walraven
C
MM
Mamdani
,Wells PS,Williams JI. Inhibition of serotonin reuptake by antidepressants and upper gastrointestinal bleeding in elderly patients: retrospective cohort study. BMJ 2001; 323:655 –8 .
4.
Moses-Kelko
EL
D
Bogen
Perel
J
2372 –83 .
5.
National Teratology Information Service, Regional Drug and Therapeutics Centre, Newcastle. Use of paroxetine in pregnancy. Accessed 28 Sept 2005.
6.
Chambers
CD
S
Hernandez-Diaz
Van Marter
LJ
579 –87 .
7.
Cipriani
A
C
Barbui
Suicide
Geddes JR.
, depression and antidepressants. Editorial. BMJ 2005; 330:373 –4 .
8.
Simon
GE
J
Savarino
B
Operskalski
,Wang PS. Suicide risk during antidepressant treatment. Am J Psychiatr 2006; 163:41 –7 .
9.
Juurlink
DN
, DN, Mamdani MM, Kopp A, Redelmeier DA. The risk of suicide with selective serotonin reuptake inhibitors in the elderly. Am J Psychiatr 2006; 163:813 –21 .
10.
Committee on Safety of Medicines. Selective serotonin reuptake inhibitors – use in children and adolescents with major depressive disorder. Accessed 10 December 2003 .